Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages.

Area of Science:

• Immunology
• Pulmonology
• Critical Care Medicine

Background:

• Acute respiratory distress syndrome (ARDS) is a critical condition with high mortality and no effective pharmacological treatments.
• The role of the programmed cell death protein 1 (PD-1) and PD-ligand 1 (PD-L1) axis in ARDS immunosuppression is not well understood.
• Soluble PD-L1 (sPD-L1) is a potential activator of the PD-1 pathway.

Purpose of the Study:

• To investigate the role of the PD-1/PD-L1 axis in ARDS.
• To explore the potential of sPD-L1 as a therapeutic agent for ARDS.
• To identify prognostic indicators for ARDS patients.

Main Methods:

• High-throughput mass cytometry was used to analyze immune cells in ARDS models.
• Monocyte/macrophage depletion was employed in mice to assess the role of these cells.
• sPD-L1 administration was tested in mice with direct ARDS.

Main Results:

• sPD-L1 levels were upregulated in survivors of direct ARDS compared to non-survivors.
• Administration of sPD-L1 in mice with direct ARDS reduced lung inflammation and improved survival.
• sPD-L1 treatment led to a decrease in proinflammatory monocyte-derived macrophages (MDMs) and induced MDM apoptosis.
• PD-1 expression was increased in MDMs of patients and mice with direct ARDS.

Conclusions:

• sPD-L1 has a protective role in direct ARDS, mediated by reducing pro-inflammatory macrophages.
• The PD-1/PD-L1 axis, particularly sPD-L1, represents a potential therapeutic target for ARDS.
• sPD-L1 serves as a prognostic indicator for patients with direct ARDS.